Clinicopathological study of ABO blood types in prostate cancer

Sushma Shankar1*, CSBR Prasad2

1Assistant Professor, Dept. of Pathology, East point College of Medical Sciences and Research Centre, Bangalore, Karnataka,
2Professor, Dept. of Pathology, Sri Devaraj Urs Medical College, Kolar, Karnataka, India

*Corresponding Author: Sushma Shankar
Email: dr.sushma1985@gmail.com

Received: 30th April, 2018
Accepted: 3rd May, 2018

Abstract
Aim: To study the association between the ABO blood groups and clinicopathological features in cases of prostate cancer (PCa).

Materials and Methods: Fifty cases of PCa, diagnosed on transurethral resection of prostate chips were a part of the study. Cases were classified into low risk and high risk categories and these categories were compared with the clinicopathological features and ABO blood groups.

Results: In the study of 50 cases, 44 cases belonged to the high risk category with 33(75%) patients being of non O blood group and 11(25%) being of the O blood group. Patients of non O group had an increased risk of aggressive PCa on comparison with the blood type O. Chi square test showed no significant difference between the non O and O groups regarding PSA value, Gleason score, tumor stage, node positivity and bone metastasis individually (p=0.418, p=0.967, p=0.506, p=0.775, p=0.549.) However within the high risk category, a statistically significant value was found for non O blood group against O groups (p=0.04) which was further proven by regression analysis.

Conclusion: In this study, non O blood types (especially A and B but not AB) were found to be independent predictors for high risk PCa and O blood type patients had a low risk of aggressive PCa thus emphasising the importance of blood typing in patients with PCa.

Keywords: Prostate cancer (PCa), ABO blood type, O blood type, Non O blood type.

Introduction
Prostate cancer (PCa) is the second common type of cancer and stands in the sixth position amongst cancer related deaths in men worldwide. The number of new PCa cases is expected to reach 1.7 million by 2030 with 4,99,000 new deaths.1

Unlike the previous belief of PCa being an entity of the western world, developing countries like India are fast catching up in numbers due to many factors like modernised life style, increased disease awareness, increased life expectancy and access to medical facilities. PCa is recorded the second common site of cancer among males in India.2

The prognostic role of Clinical (TNM) stage, prostate-specific antigen (PSA) levels and Gleason score on biopsy specimens is far beyond established in PCa. With raising incidence of PCa, it is the need of the hour to identify possible additional prognostic factors like the ABO blood groups which may help in further management of these cases.

A or B blood group antigens are complex carbohydrate molecules that are present on the RBC membrane. They determine the blood group of a person. In addition to their expression on the RBC surface, they are also expressed on the surface of epithelium, sensory neurons, platelets, and the vascular endothelium; thus extending its clinical significance beyond transfusion medicine.3 ABO blood groups have an association with non neoplastic diseases like cardiovascular diseases, infectious diseases, peptic ulcer and malignancies like carcinoma pancreas, epithelial ovarian tumors, renal cell carcinomas, nasopharyngeal cancers and skin cancers4. For example, it was shown that non O blood groups are an important risk factor for developing gastric and pancreatic cancers.4

ABO blood group types as a risk factor for cancers like gastric and pancreatic cancers have been extensively studied, whereas studies with regard to ABO blood types and PCa are seldom. A single study showed no association between blood type and risk of PCa.5 On the contrary a positive association has been observed in another study.6 Based on these facts and controversies, the present study was undertaken to establish the association if any between ABO blood group types and clinicopathological features.

Materials and Methods
Fifty cases of primarily diagnosed, pathologically confirmed PCa were a part of the study. The study was undertaken in the pathology department of Sri Devaraj Urs Medical College. The source of data was the transurethral resection of prostate chips (TURP) samples which were sent from the Urology department of the attached hospital. The clinical history of age, hypertension, diabetes, TNM stage, serum PSA levels and ABO blood types were obtained from the clinical case file database and the pathological data of gleason score and grade were collected from pathology file database. The American Joint Committee on Cancer (AJCC) TNM classification of malignant tumors 2002 was used to assess the clinical TNM stage and ISUP

Indian Journal of Pathology and Oncology, October-December, 2018;5(4):675-679 675
classification of 2005 was used for gleason scoring and grading.  

PCA patients who had other cancers and cases which lacked complete clinical and pathological information were excluded from the study.

The subjects were stratified into two risk categories: the low risk category and the high-risk category. This was based on the PSA values, Gleason score, and TNM stage. PSA ≤ 30 ng/ml, Gleason Score ≤ 7, and TNM stage ≤ T2b were categorised into low risk and high risk was defined by PSA > 30 ng/ml, Gleason Score ≥ 8, or clinical stage ≥ T2c.

Statistical Analysis

The data was entered into the SPSS software (version 20.0) and was analysed by suitable tests. Variables were expressed as mean±standard deviation (SD) or as numbers and percentages depending on the type of variable in use. Students independent t-test and chi-square test were used for analysing quantitative and qualitative data respectively. Logistic regression analysis was used to find the association between different blood types and the high risk category of PCa. Multivariate analysis was performed after adjusting for the confounding factors. P value of <0.05 was considered to be of statistical significance.

Results

Table 1: Association of clinicopathological characters with the low & high risk categories of PCa

<table>
<thead>
<tr>
<th>Characters</th>
<th>All Subjects (n=50)</th>
<th>Low risk category (n=6)</th>
<th>High risk category (n=44)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>66.2±9.4</td>
<td>70±0.2</td>
<td>65.68±9.9</td>
<td>0.028</td>
</tr>
<tr>
<td>Hypertension</td>
<td>15(30%)</td>
<td>2(4%)</td>
<td>13(26%)</td>
<td>0.849</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>13(26%)</td>
<td>2(4%)</td>
<td>11(22%)</td>
<td>0.191</td>
</tr>
<tr>
<td>PSA</td>
<td></td>
<td></td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>&lt;30ng/ml</td>
<td>8(16%)</td>
<td>5(10%)</td>
<td>3(6%)</td>
<td></td>
</tr>
<tr>
<td>&gt;30ng/ml</td>
<td>42(84%)</td>
<td>1(2%)</td>
<td>41(82%)</td>
<td></td>
</tr>
<tr>
<td>Gleason score</td>
<td></td>
<td></td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>&lt;/=6</td>
<td>8(16%)</td>
<td>6(12%)</td>
<td>2(4%)</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>14(28%)</td>
<td>0(0%)</td>
<td>14(14%)</td>
<td></td>
</tr>
<tr>
<td>8-10</td>
<td>28(56%)</td>
<td>0(0%)</td>
<td>28(28%)</td>
<td></td>
</tr>
<tr>
<td>Stage</td>
<td></td>
<td></td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Tumor</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;/=T2b</td>
<td>12(24%)</td>
<td>6(12%)</td>
<td>6(12%)</td>
<td></td>
</tr>
<tr>
<td>&gt;/=T2c</td>
<td>38(76%)</td>
<td>0(0%)</td>
<td>38(76%)</td>
<td></td>
</tr>
<tr>
<td>Node</td>
<td></td>
<td></td>
<td></td>
<td>0.221</td>
</tr>
<tr>
<td>N0</td>
<td>41(82%)</td>
<td>6(12%)</td>
<td>35(70%)</td>
<td></td>
</tr>
<tr>
<td>N1</td>
<td>9(18%)</td>
<td>0(0%)</td>
<td>9(18%)</td>
<td></td>
</tr>
<tr>
<td>Metastasis</td>
<td></td>
<td></td>
<td></td>
<td>0.709</td>
</tr>
<tr>
<td>M0</td>
<td>49(98%)</td>
<td>6(12%)</td>
<td>35(70%)</td>
<td></td>
</tr>
<tr>
<td>M1</td>
<td>1(2%)</td>
<td>0(0%)</td>
<td>1(2%)</td>
<td></td>
</tr>
<tr>
<td>ABO type</td>
<td></td>
<td></td>
<td></td>
<td>0.811</td>
</tr>
<tr>
<td>O</td>
<td>14(28%)</td>
<td>2(4%)</td>
<td>12(24%)</td>
<td></td>
</tr>
<tr>
<td>A</td>
<td>16(32%)</td>
<td>2(4%)</td>
<td>14(28%)</td>
<td></td>
</tr>
<tr>
<td>B</td>
<td>14(28%)</td>
<td>2(4%)</td>
<td>12(24%)</td>
<td></td>
</tr>
<tr>
<td>AB</td>
<td>6(12%)</td>
<td>0(0%)</td>
<td>6(12%)</td>
<td></td>
</tr>
<tr>
<td>O/ Non O type</td>
<td></td>
<td></td>
<td></td>
<td>0.662</td>
</tr>
<tr>
<td>O</td>
<td>13(26%)</td>
<td>2(4%)</td>
<td>11(22%)</td>
<td></td>
</tr>
<tr>
<td>Non O</td>
<td>37(74%)</td>
<td>4(8%)</td>
<td>33(66%)</td>
<td></td>
</tr>
</tbody>
</table>

50 pathologically confirmed cases of cancer prostate were included in the study with a mean age of 66.2±9.4 years. The tumor stage of cases was as follows: T1 (6 cases), T2a (4 cases), T2b (6 cases), T2c (6 cases), T3 (20 cases), and T4 (8 cases). 14(28%) cases were blood group O, 16(32%) cases were group A, 14(28%) cases were group B and 6(12%) were group AB. Patients with advanced age, PSA value of more than 30, gleeason score of more than 7 and the clinical tumor stage of >/=T2c had increased risk of PCa and had significant P value less than 0.05, however we did not find a significant association between the different risk groups and ABO blood types (p value=0.811). Table 1 shows a summary of the association between the clinicopathological variables and different risk categories with a significant P value written in bold.
Table 2: Pathological characters of PCa patients stratified by blood group types

<table>
<thead>
<tr>
<th>Characters</th>
<th>ABO type</th>
<th>Non O type</th>
<th>P value¹</th>
<th>P value²</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>O</td>
<td>A</td>
<td>B</td>
<td>AB</td>
</tr>
<tr>
<td>PSA</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;20</td>
<td>3(21.4%)</td>
<td>3(18.8%)</td>
<td>2(14.3%)</td>
<td>0(0%)</td>
</tr>
<tr>
<td>&gt;20</td>
<td>11(26.2%)</td>
<td>13(31%)</td>
<td>12(28.6%)</td>
<td>6(14.3%)</td>
</tr>
<tr>
<td>Gleason score</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;=6</td>
<td>2(14.3%)</td>
<td>4(25%)</td>
<td>2(14.3%)</td>
<td>0(0%)</td>
</tr>
<tr>
<td>7</td>
<td>4(28.6%)</td>
<td>4(25%)</td>
<td>2(14.3%)</td>
<td>4(66.7%)</td>
</tr>
<tr>
<td>8-10</td>
<td>8(57.1%)</td>
<td>8(50%)</td>
<td>10(71.4%)</td>
<td>2(33.3%)</td>
</tr>
<tr>
<td>Stage</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tumor</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;=T2b</td>
<td>4(28.6%)</td>
<td>4(25%)</td>
<td>2(14.3%)</td>
<td>2(33.3%)</td>
</tr>
<tr>
<td>&gt;T2c</td>
<td>10(71.4%)</td>
<td>12(75%)</td>
<td>12(85.7%)</td>
<td>4(66.7%)</td>
</tr>
<tr>
<td>Node</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N0</td>
<td>12(85.7%)</td>
<td>14(87.5%)</td>
<td>10(83.2%)</td>
<td>5(71.4%)</td>
</tr>
<tr>
<td>N1</td>
<td>2(14.3%)</td>
<td>2(12.5%)</td>
<td>4(28.6%)</td>
<td>1(16.7%)</td>
</tr>
<tr>
<td>Metastasis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M0</td>
<td>14(100%)</td>
<td>16(100%)</td>
<td>14(100%)</td>
<td>5(98%)</td>
</tr>
<tr>
<td>M1</td>
<td>0(0)</td>
<td>0(0)</td>
<td>0(0)</td>
<td>1(16.7%)</td>
</tr>
<tr>
<td>High risk</td>
<td>12(27.3%)</td>
<td>14(31.8%)</td>
<td>12(27.3%)</td>
<td>6(13.6%)</td>
</tr>
<tr>
<td>category</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

P value¹ is comparison of characters with ABO blood types, P value² is comparison of characters with O against non O type.

Evaluation of the clinicopathological characteristics according to ABO blood types (O and non O types) was done as shown in Table 2. PSA value, Gleason score, tumor stage, node positivity and bone metastasis showed no significant association (p=0.418, p=0.967, p=0.506, p=0.775, p=0.549) to any particular blood group. Out of the 44 cases of high risk PCa, 33(75%) belonged to the non O blood groups and 11 (25%) belonged to the O group. The non O blood groups as a whole showed a statistically significant association with high risk category of PCa (p=0.04) on comparison with O group. In the non O group, groups A and B had a high risk percentage (31.8% and 27.3%) whereas the AB group had a low risk percentage (13.6%) of developing PCa. This association was further analysed by regression analysis.

Table 3: Univariate logistic regression analysis in high risk PCa patients

<table>
<thead>
<tr>
<th>Characters</th>
<th>Odds ratio</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypertension</td>
<td>0.419</td>
<td>0.009</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>0.333</td>
<td>0.002</td>
</tr>
<tr>
<td>PSA</td>
<td>13.6</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Gleason score</td>
<td>10.2</td>
<td>0.002</td>
</tr>
<tr>
<td>O against non O blood types</td>
<td>3.000</td>
<td>0.002</td>
</tr>
</tbody>
</table>

Univariate logistic regression analysis was used to correlate ABO Blood Types and other clinicopathological features with reference to high risk category. As shown in Table 3, parameters including hypertension, diabetes mellitus, PSA, Gleason score, and blood type O against non O were found to be statistically significant in univariate analyses (p=0.009, p=0.002, p=0.001, p=0.002 and p=0.002) and further, were analysed by multivariate analysis. The significance of PSA, Gleason score and O against non O blood types in high risk PCa patients persisted (p<0.001) after adjusting for the confounding factors. From the above results, we inferred that non O blood groups can be used as a predictor for aggressive PCa. The association of age, hypertension, diabetes mellitus and high risk PCa was nullified on multivariate analysis.

Discussion

Prostate cancer (PCa) is the second most common cancer occurring in Indian males. With increasing expectancy of life, more number of elderly men alive and changing lifestyles, the incidence of PCa is on the rise. PSA, TNM stage and Gleason score are known risk factors of PCa.¹ ² Significance of ABO blood types in several cancer types is well established. In the year 1953, Arid et al for the first time revealed an association between ABO blood types and gastric carcinoma,³ ever since till date many investigators have extensively researched on the clinicopathological significance of ABO blood groups in different human cancers.

In the Indian setup, where the ethnic, demographic and racial characters are different from other setups where similar studies were undertaken, there is a paucity of studies which evaluate the significance of
we suggest, the uncertain role of ABO. These, a, the association of ABO
Indian Journal of Pathology and Oncology, October
should results of the present study
in this regard are a need of the hour. Based on the
specific blood groups in certain cancers, further studies
blood types in them and given the association of
involved in tumorigenesi
gastric,
irrespective of the blood group type, however the
positivity and distant metastasis remained same
primary marker for high risk PCa.
prognostic factor for aggressive PCa,
regard to the risk in PCa cases. We established that the
blood types and
cases revealed that patients with
PCa. Hence the present
study was undertaken, the first one of its kind in Indian
setup. We concluded that O blood type had a lower risk
of developing PCa and the tumor behaved less
aggressively in comparison with non O blood types.
This association remained independent and significant
on multivariate analysis after adjusting for the
confounding factors. Our study has provided thoughtful
insights into the clinical importance of ABO typing in
PCa patients with regard to the risk assessment.

ABO surface antigens are highly expressed on
RBC membranes, tissues, most epithelial and
endothelial cells. These antigens help in adhesion,
maintaining membrane structural integrity, and
transportation of molecules across membranes.

The association between ABO blood groups and
leukemias- Acute lymphoblastic leukemia was proven
to be significant with an increase in risk for AB blood
type. The non O blood group type patients had an
increased risk of head & neck cancers, pancreatic
cancer, ovarian cancer, renal cancer and gastric
cancer.

We reviewed the literature for studies on
clinicopathological risk factors for PCa and found that,
Markt et al in their study of 2,774 cases had reported no
difference between varied blood group types and risk of
PCa. On the contrary a study by Wang et al on 277
cases revealed that patients with non O blood type had
greater risk of aggressive PCa, suggesting that non O
cases should be given more clinical attention.

In our study, we studied the association of ABO
blood types and other clinicopathological features with
regard to the risk in PCa cases. We established that the
non O blood groups are an important predictor and
prognostic factor for aggressive PCa, serving it as a
primary marker for high risk PCa. Incidence of node
positivity and distant metastasis remained same
irrespective of the blood group type, however the
general trend of O blood type association with low risk
prevailed.

The outcome of present study is in concordance
with other studies where an association was found
between the non O blood groups and cancers like
gastric, pancreatic, breast, colorectal, ovarian,
nasopharyngeal and esophageal cancer. Therefore,
our data has thrown light with regard to the clinical
application of ABO blood types in cancers.

Considering the complexity of mechanisms
involved in tumorigenesis, the uncertain role of ABO
blood types in them and given the association of
specific blood groups in certain cancers, further studies
in this regard are a need of the hour. Based on the
results of the present study, we suggest patients of the
non O blood groups may have an increased risk and
should be evaluated thoroughly.

Non O blood type PCa cases require a more
aggressive treatment protocol with radical
prostatectomies. It was found that patients with B and O
blood groups fared better with vaccine therapy in
comparison with other groups, thus stressing on the
need for blood group evaluation in PCa patients. Blood
grouping may act as a cost effective tool for selection of
patients who have a chance to benefit from vaccine
therapy.

Recurrence rates of prostate cancer was low in O
blood types further supporting our findings of
association of O blood type with low risk prostate
cancer.

Limitations of the present study were 1. Being an
observational, cross sectional study, the long term
prognostic outcome of these patients was not analysed.
2. Single centre study. 3. Small case number. Given, the
outcome of the present study, large multicentre studies
in this regard are needed to throw more light in this
unexplored area.

Conclusion
The present study has provided first hand evidence
regarding the association between the non O blood
groups and increased risk of aggressive PCa. We
conclude that non O blood type can be a predictor of
high risk PCa. Further genetic and molecular research is
needed in this regard to establish the mechanisms
involved in the blood group- tumor association.

References
1. Ferlay J., Shin H.R., Bray F. International Agency for
Research on Cancer; Lyon, France: 2010. GLOBOCAN
2008, Cancer Incidence and Mortality Worldwide: IARC
Cancer Base No. 10.
2. Jain, Shalu, Sunita Saxena, and Anup Kumar.
“Epidemiology of Prostate Cancer in India.” Meta Gene
2014; 596–605.
S. “Association of ABO Blood Types and
Clinicopathological Features of Prostate Cancer”. Disease
4. Liambruno GM, Franchini M. “Beyond
immunohaematology: the role of the ABO blood group in
human diseases”. Blood Transfusion. 2013;11(4):491-
499.
cancer risk—A cohort study of 339,432 subjects in
Taiwan” Cancer epidemiology. 2015;39(2):150-156.
6. I. Epstein, W. C. Allsbrook Jr., M. B. Amin, L. L.
Egeva, and ISUP Grading Committee. The 2005
International Society of Urological Pathology (ISUP)
consensus conference on Gleason grading of prostatic
carcinoma,” The American Journal of Surgical
Pathology, 2005;29:1228–1242.
between cancer of stomach and the ABO blood
8. M.E. Reid and N. Mohandas, “Red blood cell blood
group antigens: structure and function”. Seminars in
Hematology. 2004;41:93–117.
“Distribution of ABO blood groups in childhood acute
Clinicopathological study of ABO blood types in prostate cancer


How to cite this article: Shankar S, Prasad CSBR. Clinicopathological study of ABO blood types in prostate cancer. Indian J Pathol Oncol. 2018;5(4):675-679.